Insulin Auto Antibody

Diabetes

Report in 96Hrs

At Home

No Fasting Required

Details

Measures insulin level.

₹2,516₹3,594

30% OFF

Insulin Auto Antibody Test Information Guide

Why is it done?
- Detects autoimmune antibodies directed against insulin, indicating the body's immune system is attacking insulin-producing cells
- Screens for Type 1 diabetes risk, particularly in first-degree relatives of individuals with Type 1 diabetes
- Helps identify children at high risk for developing Type 1 diabetes before clinical symptoms appear
- Differentiates Type 1 diabetes from Type 2 diabetes or other forms of diabetes
- Typically performed during newborn screening programs or during initial diabetes evaluation in symptomatic patients
- Part of multiple autoantibody testing (along with GAD65, IA-2, and ZnT8) for comprehensive autoimmune diabetes screening
Normal Range
- Negative Result: <0.4 U/mL or <0.4 IU/mL (varies by laboratory); indicates absence of insulin autoantibodies
- Borderline/Equivocal: 0.4-1.0 U/mL; may indicate low-level antibodies or early immune response; requires repeat testing
- Positive Result: >1.0 U/mL; indicates presence of insulin autoantibodies and increased risk for autoimmune diabetes
- Units of Measurement: U/mL (Units per milliliter) or IU/mL (International Units per milliliter); specific cutoff values vary by laboratory methodology
- Interpretation: Normal result indicates no detectable autoimmune response against insulin; abnormal (positive) result suggests autoimmune beta cell destruction is occurring
Interpretation
- Single Positive IAA Result: Indicates presence of insulin autoimmunity; requires repeat testing to confirm and should be evaluated with other diabetes autoantibodies (GAD65, IA-2, ZnT8)
- Multiple Positive Autoantibodies (≥2): Strong predictor of Type 1 diabetes development; 70-90% risk of developing clinical diabetes within 5 years, especially in children
- Negative Result with Symptoms: May suggest Type 2 diabetes, MODY, neonatal diabetes, or secondary diabetes; warrants additional testing including C-peptide, genetic testing, or imaging
- Borderline Results: Repeat testing in 3-6 months recommended; results may convert to positive, negative, or remain stable
- Factors Affecting Readings: Laboratory methodology differences, sample handling, timing relative to symptom onset, cross-reactivity with other autoantigens, age at testing, and ethnic background
- Clinical Significance: IAA is most frequently the first autoantibody to appear in young children but may disappear in older children and adults; presence indicates ongoing autoimmune beta cell attack
Associated Organs
- Primary Organ System: Pancreas (specifically the islets of Langerhans, beta cells); endocrine system
- Type 1 Diabetes Mellitus: Autoimmune destruction of insulin-producing beta cells; IAA is a marker of this process
- Latent Autoimmune Diabetes in Adults (LADA): Slow-onset autoimmune diabetes; may present as Type 2 diabetes but has autoimmune component with positive IAA
- Potential Complications of Abnormal Results: Progressive beta cell destruction leading to severe hyperglycemia, diabetic ketoacidosis (DKA), hypoglycemia, microvascular complications (retinopathy, nephropathy, neuropathy), and macrovascular disease
- Associated Autoimmune Diseases: Thyroid disease (Graves' disease, Hashimoto's thyroiditis), celiac disease, Addison's disease, vitiligo, and other autoimmune endocrinopathies may coexist
- Metabolic Complications: Hyperglycemia, ketosis, dehydration, and electrolyte imbalances from uncontrolled diabetes
Follow-up Tests
- Other Diabetes Autoantibody Panel: GAD65 (glutamic acid decarboxylase-65), IA-2 (insulinoma-associated antigen-2), and ZnT8 (zinc transporter 8) autoantibodies for comprehensive autoimmune diabetes assessment
- Fasting Blood Glucose: Screen for hyperglycemia and diabetes development
- Hemoglobin A1C (HbA1C): Assess average blood glucose over 2-3 months to diagnose diabetes and monitor glycemic control
- Oral Glucose Tolerance Test (OGTT): Dynamic glucose challenge to detect impaired glucose tolerance or diabetes in asymptomatic individuals
- C-Peptide Level: Assess remaining beta cell function and distinguish autoimmune diabetes from other types
- Thyroid Function Tests (TSH, Free T4): Screen for associated autoimmune thyroid disease in autoimmune diabetes patients
- Tissue Transglutaminase (tTG) IgA: Screen for celiac disease, which frequently coexists with Type 1 diabetes
- Repeat IAA Testing: For borderline results, repeat in 3-6 months; for positive single antibody, repeat to confirm persistence; monitor for antibody development pattern
- Monitoring Frequency: At-risk relatives: repeat screening every 1-2 years; positive patients: fasting glucose and HbA1C every 3-6 months; diagnosed diabetics: HbA1C every 3 months until stable, then quarterly or semi-annually
Fasting Required?
- Fasting Required: No
- Explanation: Insulin autoantibodies are not affected by food intake; blood sample can be drawn at any time of day with or without recent meals
- Patient Preparation: Minimal preparation required; inform phlebotomist of any bleeding disorders or anticoagulant use; remain seated or lying down for 5 minutes before blood draw to reduce dizziness
- Medications to Avoid: No specific medications need to be avoided for this test; however, inform laboratory if taking immunosuppressants or biologics that may affect autoimmune response
- Special Instructions: Blood sample should be collected in appropriate serum separator or EDTA tube per laboratory protocol; proper specimen handling is crucial for accurate antibody detection; if borderline result obtained, recommend repeat testing from same laboratory for consistency; samples may require refrigeration or freezing for shipping to specialized reference laboratories

How our test process works!